The Days of Peer-Reviewed Articles for Computer Science Review Are Ending

Results of Research Become Available Much More Quickly, Says Jason Mars

ANN ARBOR, MI, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Traditionally, all computer science research papers underwent a review process to determine whether the paper met the publication criteria for trade research journals. The reviewers were professors and senior researchers who decided whether the paper made a significant contribution to the industry. This "program committee" served as editors for the scientific community. However, the advent of arXiv has changed this tradition, says Jason Mars, a professor of computer science.

ArXiv is a free open access e-archive that allows scientists in physics, math, computer science, and related disciplines to share articles globally before the research is published. While some of the papers self-published on ArXiv are insignificant, many of them represent top-notch research work, says Jason Mars.

"The most impactful papers in AI (artificial intelligence) were published on arXiv before ever being published in a peer-reviewed venue," says Jason Mars. Publishing on arXiv allowed the AI field to progress faster than it would have if the scientists had waited for peer-review without publishing, Jason Mars says. "ArXiv is first to market with everything."

New technologies are coming out so quickly that the possibility of an idea getting scooped is increasing. Researchers are pressured to put their ideas out quickly, says Jason Mars. Peer review, however, takes several months. "The general sense of the community is that "ain't nobody got time for that!" says Jason Mars. The result is that scientists turn to ArXiv to put their ideas out quickly.

When scientists self-publish on ArXiv and open-source their research code, others also can run the code to test it to see if the new technique is better than the old method. In this way, the crowd becomes the reviewer, says Jason Mars, resulting in an economy of ideas and a competitive market for contributions. In this way, ArXiv has disrupted the space. "No longer will we have a group of greybeards deciding on what ideas hit the world," says Jason Mars.
As the world becomes ever more digital, this trend will exacerbate, and "I say good riddance to the old and in with the new," says Jason Mars. "The economic dynamism of the market is the most durable meritocracy that has yet emerged."

About Jason Mars

Jason Mars is a computer science professor at the University of Michigan, where he directs Clarity Lab. Clarity Lab is one of the best places in the world to be trained in topics spanning artificial intelligence, large scale computing, and programming languages. Among numerous contributions, his lab pioneered award-winning work on Sirius (aka Lucida). Sirius is the world's first-open source sophisticated virtual assistant that simultaneously hears, sees, and understands.
Jason Mars also founded Clinc, a record-breaking cutting-edge AI company based in Ann Arbor, Michigan. At Clinc, he led the development of the world's most advanced conversational AI, which was first applied to the banking industry and then later to the healthcare, automotive, and food services industries. From 2015 to 2020, Clinc experienced substantial year-over-year growth employing 120 employees and raising more than $62 million in venture capital. Under his leadership, the business has grown to about $10 million in ARR, and its AI products have more than 7 million active users.

Caroline Hunter
Web Presence, LLC
+1 786-233-8220
email us here

Why conversational AI is taking over our world


Source: EIN Presswire

Dr. Sung Yang Explains How Preventing Severe COVID-19 Cases is About Controlling Chronic Conditions

Dr. Sung Yang Explains How Preventing Severe COVID-19 Cases is About Controlling Chronic Conditions

COVID-19

In an Effort to Reduce Severe COVID-19 Cases, Dr. Sung Yang Explores Existing Chronic Conditions

HONOLULU, HI, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Throughout the history of COVID-19, medical professionals have noted that most people with severe cases have other health problems. Those who are healthy will often encounter only mild to moderate flu-like symptoms. Dr. Sung Yang explores how managing existing chronic conditions can help prevent severe COVID-19 cases.

Dr. Sung Yang is a physician based in Honolulu, Hawaii. He has been exploring a number of aspects regarding COVID-19, including the way to prevent severe infections. He has found that by working with his patients, it’s possible to reduce the risk of severe COVID-19 cases with complications.
One of the things that Dr. Sung Yang recommends is identifying the various chronic medical conditions that a person has. Particularly as it pertains to CovidOVID-19, certain conditions can make the virus to become more aggressive or the immune system more vulnerable to the virus. Dr. Sung Yang explains that many of these conditions are already familiar and include but not limited to diabetes, high blood pressure, obesity, coronary artery disease, asthma, COPD, chronic kidney disease, and cancer.

Not all patients have their chronic conditions under control. Now more than ever is the time that Dr. Sung Yang recommends that patients need to achieve maximum control. In some instances, it may be necessary to focus on medications. In other instances, it is necessary to transform the lifestyle by eating healthy, exercising more and losing weight.

A patient who has chronic conditions that are out of control are more likely to have a rough go of time with COVID-19. The patient who tested positive for COVID-19 may need to stay in a hospital or even transfer to the ICU because he or she has difficulty with breathing that causes hypoxia, which is a critical drop in oxygen level in the circulation. Therefore, the patient needs to be connected to a ventilator machine to receive more air and oxygen through the lungs weakened and damaged by the virus. When not enough oxygen is absorbed from the lungs and transported into the circulation other vital organs such as the heart, brain, and kidneys start to not work properly and go into multiple organ failure. At the same time, the immune system becomes exhausted after fighting with the COVID-19 virus and becomes so weakened that it cannot fend off other infections by other bacteria and viruses such as the flu virus. Lastly, the immune system also becomes so altered that it behaves strangely in such a way that it allows clots to form in various blood vessels and organs even though such clots are not needed. All of these complications add more time, medications, procedures as well as more suffering to the hospitalization and even death in many unfortunate scenarios.

Dr. Sung Yang has a goal to keep his patients out of the ER, the hospital and of course the ICU. By helping patients better control their chronic conditions Dr Sung Yang keeps the COVID-19 patients quarantined at home with just mild symptoms. Dr. Sung Yang believes that education is the key. During regular in-person or telemedicine visits Dr. Sung Yang emphasizes this prevention against severe COVID-19 infections.

In addition to focusing on optimizing the control of chronic conditions, Dr. Sung Yang is also an advocate of rapid and accurate COVID-19 testing. He believes that patients will have a better chance of avoiding the coronavirus entirely if it’s possible to know who has been exposed to the virus.
Dr. Sung Yang recommends that anyone with chronic medical conditions focus on getting them under maximum control now rather than later because once a person is hospitalized due to severe COVID-19 infection it is too late.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here


Source: EIN Presswire

Dr. Frank Roach, Atlanta Dentist, Discusses the Top 3 Signs You Need to See a Dentist

Dr. Frank Roach

Dr. Frank Roach

ATLANTA, GA, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Dr. Frank Roach Atlanta dentist sees dozens of patients every day, and over his two decades of experience, he has learned what symptoms can wait and which mean you need to see a dentist immediately.

See Your Dentist If You’re Experiencing Tooth Pain Says Dr. Frank Roach Atlanta Dentist

“Toothaches are always a sign that something deeper is wrong,” says Dr. Frank Roach Atlanta dentist. He explains that temporary, random, or passing pain is likely nothing to worry about. “You may just have some tooth sensitivity.”

But if you are experiencing prolonged, sharp, or worsening pain, it’s time to call the dentist. “Typically your pain is only going to worsen over time,” says Dr. Frank Roach Atlanta. “And if it’s an infection or an abscess, you’re risking it spreading to other areas of your mouth. That’s a much more painful and expensive treatment process.”

If You Find White Spots On Your Gums or Teeth Seek Treatment Says Dr. Frank Roach Atlanta

If you see white spots on your teeth, you should schedule a dentist appointment, says Dr. Frank Roach Atlanta. White spots on your tooth’s enamel are one of the first signs of tooth decay. “If you catch it early, you can prevent a cavity – and possibly having to undergo the drilling and filing process.
“It’s so much cheaper to treat the problem proactively than it is to deal with the aftermath,” says Dr. Roach.

On your gums, white spots are a sure sign of infection. “You may not have any pain in your tooth yet, but it’s coming for you if you have white spots on your gums,” says Dr. Frank Roach Atlanta. He advises you not to pop or scrape the spot as you could inadvertently spread infection. Instead, call your dentist right away.

Dry Mouth Can Be a Warning Sign Says Dr. Frank Roach Atlanta

“Dry mouth can be caused by any number of conditions or medications,” says Dr. Roach. But while dry mouth is a common experience, consistent and repeated dry mouth can be a sign of chronic conditions. And no matter what causes it, dry mouth can cause gum disease and promote bacterial growth. Schedule an appointment with your dentist to discuss treatment options. Medicated mouthwashes can help tremendously with dry mouth aggravation and symptoms.

Dr. Frank Roach Atlanta dentist has been serving Atlanta for over 20 years. He constantly strives to stay at the top of his profession by using the latest techniques, materials, and technology. He takes great pride in providing the best dental care available.

Caroline Hunter
Web Presence, LLC
+1 786-233-8220
email us here


Source: EIN Presswire

Antibiotics Market to Reach $50.37 Billion by 2025 at 2.1% CAGR

Antibiotics Market

Antibiotics Market

Rise in consumption of antibiotics in low & middle-income countries heavy investments for R&D by biotech companies would propel the growth of antibiotics market

PORTLAND, OR, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Allied Market Research published a report, titled, Antibiotics Market by Class (Beta Lactam and Beta Lactamase Inhibitors (Penicillins, Cephalosporins, Carbapenems, and Monobactams), Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum antibiotic and Narrow-spectrum antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018-2025. The report provides detailed analyses of the top winning strategies, driving forces & opportunities, key market segments, competitive landscape, and strategic developments. As per the report, the global antibiotics market generated $42.33 billion in 2017 and is expected to reach $50.37 billion by 2025, registering a CAGR of 2.1% from 2018 to 2025.

Increasing utilization of antibiotics in low and middle-income countries (LMICs) due to high incidence of severe infections, high capital allocation for R&D activities by biotech companies, and supportive norms and regulations drive the growth of the market. However, development of antibiotic resistance and rise in drug approval costs hinder the market growth. Conversely, discovery of advanced prospect molecules and innovative combination therapies for the treatment of antibiotic-resistant microbial infections would create opportunities for the market in future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5072

Beta lactam and beta lactamase inhibitors segment to maintain its dominance by 2025

The beta lactam and beta lactamase inhibitors segment contributed nearly two-thirds of the total market share in 2017 and is expected to maintain its dominance by 2025. This is due to rise in demand for its effectiveness in treating Gram-positive & Gram-negative bacteria as well as use in the treatment of broad-spectrum of infections. However, quinolones segment would register the fastest CAGR of 4.3% from 2018 to 2025, owing to their characteristics such as remarkable oral bioavailability, good tissue penetration, and high broad-spectrum bactericidal activity, especially in new generation quinolones. The report also analyzes macrolides and others.

Semisynthetic segment to lead throughout the forecast period

The semisynthetic segment accounted for more than one-third of the total market share in 2017 and will continue to maintain its lead by 2025. This is due to the enhanced coverage and efficacy against a wide range of organisms as well as ease in administration and cost effectiveness as compared to other antibiotics. However, the synthetic segment would register the fastest CAGR of 2.7% from 2018 to 2025 due to high demand for synthetic membrane-targeted antibiotics, broad spectrum activity, rapid bactericidal activity, no cross-resistance with existing antibiotics, and low probability of developing resistance. The report also discusses antibiotics of natural origin.

Broad-spectrum antibiotics segment to be lucrative by 2025

Broad-spectrum antibiotics segment contributed more than two-thirds of the total market share in 2017. This segment would dominate by 2025, registering the fastest CAGR of 2.4% from 2018 to 2025. This is attributed to the growing demand for broad-spectrum antibiotics to curb widespread antimicrobial resistance. The research also discusses narrow-spectrum antibiotics.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5072

Intravenous segment to dominate in terms of revenue during the forecast period

Intravenous route of administration segment accounted for nearly half of the total market share in 2017, owing to the rise in incidence of severe infections, which requires intravenous antibiotics for reaching the tissues faster and achieving higher concentrations as compared to oral antibiotics. This segment would maintain its lead position by 2025. However, the oral segment would grow at the highest CAGR of 2.5% from 2018 to 2025, owing to ease in self-administration, which results in high demand for oral drugs and reduction in hospital stay.

Asia-Pacific to register the highest revenue by 2025

Asia-Pacific region contributed more than one-third of the total market share in 2017, owing to the burgeoning rate of antibiotics consumption, ease in availability of antibiotics, and increase in sales of antibiotics without prescription. This region would continue to dominate throughout the forecast period. However, LAMEA region would grow at the fastest CAGR of 3.5% from 2018 to 2025. This is due to easy of availability and relaxed legislations or restrictions on their usage in this region.

Leading market players

The key market players analyzed in the report include Abbott Laboratories, F.Hoffmann-La Roche Ltd., Allergan Plc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG (Sandoz), Mylan N.V., Sanofi, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. They have implemented various strategies such as expansions, mergers & acquisitions, joint ventures, partnerships, collaborations, and others to achieve a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:
Global Spirulina Market Expected to Reach $779 Million by 2026
Global Healthcare Chatbots Market Expected to Reach $116.9 Million by 2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Intravenous Therapy and Vein Access Market Size Targets to Grow at a CAGR of 6.4%& to Hit $27,971 Million by 2026

IV therapy works faster for the quick immune system response and relief from chronic diseases as compared to oral mode of medication

PUNE, MAHARASHTRA, INDIA, September 23, 2020 /EINPresswire.com/ — Intravenous therapy is used to administer medicine, nutrients, blood, and buffer solution directly into the vein. IV therapy works faster for the quick immune system response and relief from chronic diseases as compared to oral mode of medication. IV therapy can be easily monitored and has infusion pump that controls the volume of the substance to be administered in the body. Increase in incidence of chronic disorders, surge in trauma cases, rise in geriatric population, and growth in road accidents are expected to boost the market growth during the analysis period. However, lack of skilled professionals is projected to restrain the market growth during the forecast period.

The intravenous catheter market segment held the highest share, owing to increase in healthcare expenditure and continuous advancement in intravenous catheter technology, which are expected to support the growth of this market during the forecast period.

Download Free Sample PDF of Report with Details COVID-19 Impact Analysis@ https://www.alliedmarketresearch.com/request-sample/2350

Medical administration held the highest market share in 2018, owing to wide use of IV therapy for medication administration as it is most effective, fast acting, and suitable for unconscious and emergency patients. The hospitals segment gained the highest market share in 2018, owing to highest number of surgical procedures in hospitals resulting in usage of IV therapy.

Market Competitive Analysis:

The major players profiled in the global IV therapy and vein access devices market are Becton, Dickinson and Company, B. Braun Melsungen AG, Terumo Medical Corporation, Teleflex Medical Inc., Medtronic Inc., Smith & Nephew plc., AngioDynamics, Inc., Pfizer Inc., Insulet Corporation, and Fresenius SE & Co. KGaA.

Covid-19 Impact on the Global Intravenous Therapy and Vein Access Market:

Intravenous Therapy and Vein Access Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Key Findings of the Intravenous Therapy and Vein Access Devices Market:

• By product, the intravenous catheter segment dominated the market in 2018, and is projected to grow at the highest CAGR during the analysis period 2020-2026.
• By application, the medication administration segment accounted for the highest share in 2018.
• U.S. was the major shareholder in the North America IV therapy and vein access devices market in 2018.
• Asia-Pacific is expected to witness the highest growth rate.
• China is expected to grow at the highest CAGR in the Asia-Pacific IV therapy and vein access devices market in 2018.

North America accounted for two-fifths share in 2016, and is expected to dominate the market throughout the forecast period. This is attributed to increase in incidence of chronic diseases due to rise in geriatric population, well-established healthcare systems, and increase in awareness among the population toward timely diagnosis and treatment of diseases. In addition, higher adoption rate for technologically advanced devices is anticipated to provide new growth opportunities for the key players in the market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, growth in demand for healthcare services from large pool of patient population, and improvement in healthcare infrastructure.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/2350

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

Digital PCR Market to Reach $1,206.46 Million by 2025 at 18.0% CAGR

Digital PCR Market

Digital PCR Market

Rise in need for early diagnosis of chronic diseases, increase in demand for innovative diagnostic techniques in health are like to growth of digital PCR market

PORTLAND, OR, UNITED STATES, September 23, 2020 /EINPresswire.com/ — Allied Market Research recently published a report, titled, "Digital PCR Market by Technology (Droplet Digital PCR (ddPCR) and BEAMing Digital PCR), Product Type (Digital PCR Equipment, Consumables & Reagents, and Software & Services), Application (Clinical Diagnostics, Research, and Forensics), and End User (Clinical Diagnostic Laboratories, Pharmaceuticals and Biotechnology Industries, and University and Government Organizations): Global Opportunity Analysis and Industry Forecast, 2018–2025". According to the report, the global digital PCR market was pegged at $318.22 million in 2017 and is projected to reach $1,206.46 million by 2025, growing with a CAGR of 18.0% through 2025.

Rise in demand for innovative diagnostic techniques and increase in health awareness have boosted the growth of the global digital PCR market. However, high cost of dPCR testing and limited expertise and accessibility in the emerging economies hinder the market growth. On the contrary, rise in need for early diagnosis of viral, genetic and infectious disease and surge in number of diagnostic centers across the globe are expected to create lucrative opportunities for the market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/654

Droplet digital PCR segment dominates the market

Droplet digital PCR segment held the largest share in 2017, contributing more than four-fifths of the total market. However, the BEAMing digital PCR segment is projected to manifest the fastest CAGR of 18.9% during the forecast period.

Software & services segment to manifest fastest growth by 2025

Software & services segment is projected to portray the fastest CAGR of 19.9% during the study period. However, consumables and reagents segment held the largest share in 2017, contributing more than half of the total market. The report also analyzes the segment of digital PCR systems.

Research segment to retain lion's share

The research segment contributed the largest share, holding nearly one-third of the market in 2017. However, the forensics segment is estimated to manifest the fastest CAGR of 18.8% during the forecast period. The report also studies the segment of clinical diagnostics.

Asia-Pacific region to portray fastest growth through 2025

Asia-Pacific region is projected to register the fastest CAGR of 17.7% during the forecast period, owing to increase in number of patients suffering from chronic diseases and improvement in healthcare facilities in the region. However, the North America region dominated the market in terms of revenue, contributing nearly half of the market, owing to presence of leading molecular diagnostics manufacturers and rise in number of patients using personalized medicines. The report also analyzes the other regions such as Europe and Latin America, Middle East and Africa (LAMEA).

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/654

Major market players

The report analyzes the major companies in the market including Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), JN Medsys, Qiagen N.V. (Formulatrix, Inc.), Expedeon AG, Sysmex Corporation (Sysmex Inostics GmbH), Fluidigm Corporation, Merck KGaA, Stilla Technologies, and Thermo Fisher Scientific, Inc.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Global Digital Pathology Market Expected to Reach $1,390 Million by 2026
Global Workplace Wellness Market Expected to Reach $74 Billion by 2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Eye Testing Equipment Market Worth $3,914 Million by 2025 | CAGR: 5.0%

Eye Testing Equipment Market

Eye Testing Equipment Market

The increase in the number of eye diseases worldwide and high-end technological advances in the field of ophthalmic diagnostics will drive the growth the market

PORTLAND, , OR, UNITED STATES, September 23, 2020 /EINPresswire.com/ — According to a new report published by Allied Market Research, titled, Eye Testing Equipment Market by Device, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2025, the eye Testing equipment market was valued at $2,638 million in 2017 and is expected to reach $3,914 million by 2025, registering a CAGR of 5.0% from 2018 to 2025. The fundus cameras segment accounted for one-sixths of the total market share in 2017.

Eye examinations include a series of tests that can assist in the evaluation of an individuals vision and check for the onset of an eye disease. The eye doctor/optometrists/ophthalmologists employ various devices that can look through an eye helping in vison analysis of an individual. Most of the eye associated ailments are treatable if detected at an early stage, thus ophthalmic diagnostic equipment plays a pivotal role in the management of increase in the burden of eye ailments across the globe. In addition, the routine eye examinations help eye care professionals to assist the patients in correction and adaptation to vision changes. This has propelled the demand for eye testing equipment across several medical settings.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4750

In addition, rise in government initiatives that are aiming at setting up guidelines to control the increase in vision impairment across the globe are compelling the key manufacturers to introduce novel eye testing equipment in the market. For instance, the Centers for Disease Control and Prevention (CDC) has initiated a program named Vision Health Initiative through which it aims at spreading awareness regarding eye abnormalities along with the present or latest diagnostic as well as treatment methods to manage the same. This in turn assists in increasing awareness pertaining to the advanced eye diagnostic/testing equipment.

The glaucoma application generated the highest revenue in 2017 and is expected to maintain its dominance throughout the forecast period. This is attributed to growth in the prevalence of glaucoma that was witnessed over the years across the globe and is expected to maintain this trend in the future. However, the cataract application segment is expected to register the highest growth rate during the forecast period. Preventive measures play an important role in the patients suffering from cataract as at initial stages cataract can be treated using drugs and eyeglasses. This has driven the demand for diagnostic devices used across this application.

Based on end user, the hospitals, eye clinics, and optometry academic institutes. Eye clinics are expected to dominate the global market throughout the forecast period. This is attributed to the fact that common eye associated disorders, which were initially untreatable can now be treated successfully in the eye clinics. This is possible through effective diagnosis while incorporating eye testing devices with low examination time that is coupled with ease of scheduling appointments across eye clinics. Moreover, rise in the number of practitioners (known as ODs) obtaining Doctor of Optometry degree (DO) from an accredited optometry school has been observed over the years. This has contributed towards the robust growth displayed by this segment from 2018-2025.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4750

Key Findings of the Eye Testing Equipment Market:

The general examination application segment accounted for two-sevenths of the total market share in 2017.
The hospital segment registered second highest growth rate among the end users registering a CAGR of 5.4% from 2018 to 2025.
North America dominated the global eye testing equipment market, accounting for maximum share in 2017, and is expected to retain the same trend during the forecast period.
The tonometer segment recorded second highest growth rate among the devices registering a CAGR of 6.8% during the forecast period.
Germany accounted for one-fifth of the total share in the European eye testing equipment market in 2017.

Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, surge in disposable income, and rise in patient awareness towards eye care. In addition, increase in the geriatric population that is highly susceptible to glaucoma and cataract is the key contributor for the market growth in the region.

The major companies profiled in this report include Carl Zeiss, Metall Zug AG (Haag Streit), Topcon Corporation, Nidek Co., Ltd., BON Optic, Novartis (Alcon), Canon, Essilor, Heine Optotechnik, and Luneau Technology. Other players operating in the eye equipment market include Heidelberg Engineering GmBH, Huvitz, Reichert Technologies, Potec, Visionix, Tomey Corporation, Escalon, and LuxVision.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:
Healthcare Chatbots Market : Global Opportunity Analysis and Industry Forecast, 2018–2026
Workplace Wellness Market : Global Opportunity Analysis and Industry Forecast, 2019–2026

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Automated Liquid Handling (ALH) Market Size Targets to Grow at CAGR of 8.7% with Industry’s Developments in 2020 – 2027

Automated liquid handling become vital tool in drug development & discovery, especially in high-throughput screening procedures comprising millions of compound

PUNE, MAHARASHTRA, INDIA, September 23, 2020 /EINPresswire.com/ — The error-free reproducibility in results offered by automated liquid handling systems is a significant advantage, which is essential when it comes to drug discovery, disease and diagnostics research in pharmaceutical and clinical settings.

Automated liquid handling (ALH) has now become a vital tool in drug development and discovery, especially in high-throughput screening procedures comprising millions of compounds. Different innovations in ALH systems have facilitated assay miniaturization, thereby exponentially accelerating the discovery of chemical probes and drug candidates for querying biological systems.

Download Free Sample PDF of Report with Details COVID-19 Impact Analysis@ https://www.alliedmarketresearch.com/request-sample/2347

"Automated Liquid Handling (ALH) Market by Type, Modality, Procedure, and End User: Global Opportunity Analysis and Industry Forecast, 2020 -2026," the global ALH market was valued at $585 million in 2016, and is projected to reach $1,054 million by 2023, growing at a CAGR of 8.7% from 2017 to 2023. The multi-instrument ALH system segment is anticipated to witness highest growth rate from 2020 to 2026 (Report Available with Recant Update)

Market Competitive Analysis:

The report provides extensive competitive analysis and profiles of key market players such as Tecan Group Ltd., Corning Incorporated, Hamilton Company, Agilent Technologies, Mettler-Toledo International Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Aurora Biomed, and Eppendorf Ag.

The other players in the value chain include Shimadzu, Roche Holding Ag, Bio-Rad Laboratories, Inc., Siemens Healthcare, Synchron Lab, and Hudson Robotics.

Covid-19 Impact on the Global Automated Liquid Handling Market:

Automated Liquid Handling Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Key Benefits:

• This report provides a detailed quantitative analysis of the current market trends from 2020 to 2026 to identify the prevailing opportunities.

• Market estimations are based on comprehensive analysis of the key developments in the industry.

• In-depth analysis based on geography assists to understand the regional market and the strategic business planning.

• The developmental strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

The major factors that drive the global ALH market are advantages of ALH systems over manual pipetting, dearth in skilled professionals, and technological advancements associated with ALH systems. In addition, rise in awareness of the benefits of using ALH is expected to fuel the market growth. However, high costs of instruments and complex operability of advanced ALH systems are expected to restrain the market growth. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.

The standalone ALH type segment occupied the highest share in ALH type market in 2016, owing to their sheer usage and availability in different research and clinical settings. The ALH PCR setup procedure segment witnessed the highest growth rate in 2016. However, the serial dilution procedure is anticipated to dominate the market.

At present, the biotechnology and pharmaceutical companies dominate the end user segment, and are expected to grow at a CAGR of 7.5% during the forecast period. This is attributable to increase in usage and application of ALH systems to carry out high-throughput screening in these companies.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/2347

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
+1 800-792-5285
email us here


Source: EIN Presswire

David Hastings Discusses How The Pandemic is Affecting Climate Change

David Hastings

David Hastings

David Hastings On How The Pandemic is Affecting Climate Change

GAINESVILLE, FL, UNITED STATES, September 23, 2020 /EINPresswire.com/ — “This is a subject that will continue to evolve as new studies are performed and new information comes out,” says Dr. David Hastings, former professor of marine science and chemistry, and current environmental activist. “But overall, the findings have been very interesting to watch.”

Certain Waterways are (Temporarily) More Clear Says David Hastings

The pictures of exceptionally clear canals in Venice during the pandemic are stunning. Without tourists using boats to explore the city, the canals cleared in a matter of weeks. Sediments, normally stirred up by the boats, settled back to the bottom of the canal and water clarity has increased dramatically. Cormorants could dive for fish, and the visual clarity meant that other life started moving into the clear water.
It was a moving example of how nature can recover when humans take a step back. But it is also a temporary condition. Tourists will return, taking their boat rides, and the water will again become turbid. The best way to conserve and protect natural systems and our environment is to bring about large-scale policy change, according to David Hastings.

“In general, many environmental systems are resilient. Given enough time, these systems can recover from harmful impacts. But only if we stop overwhelming them with the environmental insults including pollution, runoff, chemical contamination, and the impacts of climate change. Our ecosystems are remarkably resilient. However, past a certain threshold the ecosystem undergoes a regime shift, which can be permanent. These thresholds are not well understood.”

CO2 Levels Have Decreased Says David Hastings – But They’re Still Rising

While greenhouse gas emissions decreased 10-30% as a result of the pandemic, globally they will still be higher than last year. The Carbon Brief estimates that CO2 levels in the atmosphere will increase by 2.48 parts per million in 2020. This is 0.32 parts per million smaller than the expected rise – or eleven percent of the expected rise.

These numbers are evidence that it is possible to decrease the level of our individual CO2 emissions by decreasing our travel by car and plane, which are important parts of total carbon emissions. But personal transportation is not the only or most important contributor to CO2 and other greenhouse gases to the atmosphere. We have to make systemic changes that include energy sources, cement production, deforestation and farming practices to see long term results.

Single-Use Plastic Use is Rising During the Pandemic Says David Hastings

Unfortunately, the improvements we are seeing for the environment – reduced air pollution, reduced waste from restaurants and retail markets, etc. – are being outweighed by a rise in single-use plastic. The take out packaging, discarded masks and other PPE, the wrap on your jumbo pack of toilet paper ,and the plastic packaging in your online orders – it all ends up in a landfill. And some of that will eventually end up in the ocean.

Even recyclables like cardboard, cans, and glass bottles are ending up in the landfill more and more often as recycling plants are becoming overwhelmed with the influx of materials to be recycled. . David Hastings says while we are out in the world less, we are consuming more than ever. The packaging from online shopping is currently a significant source of single-use plastic in the US.

But how can we fight it? Stay safe, we need to order any essential products online. “Try to use brands that offer eco-conscious packaging solutions,” advises David Hastings. “I realize it’s not always a cost-effective option. And there are no good alternatives currently available for some products. In those cases, reach out to your favorite brands and encourage your friends to do the same.Let companies know that you, the consumer, want better options and that you’re willing to reward them with loyalty.

But eventually, for long term solutions to the problem of plastic pollution, we need to shift away from an environmental problem to an opportunity for economic development and building new businesses.”

Policy doesn’t change unless the people advocate for it, David Hastings reminds us. Tell your elected officials, your politicians, and your community leaders that you want to see change. And in the meantime, do what you can to reduce your own environmental footprint.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here


Source: EIN Presswire

OCT Clinical Recruits Final Patient for Phase III Osteoarthritis Study

OCT Clinical Logo

OCT Clinical announced it has reached target enrollment for a phase III Rheumatology study on behalf of Korean Pharmaceutical company Handok Inc.

Leading mid-size CRO in Russia works through recruitment challenges during the COVID-19 pandemic to complete enrollment on behalf of Handok Inc.

We are very pleased with the OCT Clinical team for meeting our recruitment goal under such difficult conditions.”

— BokJin Hyun, Head of Clinical Research, Handok Inc.

ST. PETERSBURG, RUSSIA, September 23, 2020 /EINPresswire.com/ — OCT Clinical, a leading Eastern European CRO headquartered in Russia, today announced it has reached target enrollment for a phase III Rheumatology study on behalf of Korean Pharmaceutical company Handok Inc.

The open, comparative, randomized study will test the efficacy and safety of an adhesive bandage for knee osteoarthritis. Handok’s Inc. treatment will be applied every 12 hours and tested against a comparator bandage applied every 24 hours.

OCT’s team met the recruitment goal within 4 months, adhering to all deadlines despite sites on lockdown, remote CRA visits, and other obstacles presented by the COVID-19 pandemic. With an effective risk-management action plan in place, OCT has successfully navigated these circumstances to keep the Sponsor’s timeline on track.

“We are very pleased with the OCT Clinical team for meeting our recruitment goal under such difficult conditions,” said BokJin Hyun, Head of Clinical Research, Handok Inc. “The achievement is quite impressive, considering the challenging circumstances imposed by the global pandemic.”

Within this project, OCT Clinical is responsible for medical writing, regulatory support, project management, medical monitoring, data management, biostatistics, logistics and pharmacovigilance.

“Our team is delighted to be able to demonstrate great performance for Handok Inc.,” said Irina Petrova, Director of Clinical Operations, OCT Clinical. “We welcome the challenge and look forward to further milestones to see to the success of the project.”

About OCT Clinical
OCT Clinical is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT’s experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at www.OCT-ClinicalTrials.com

About Handok Inc
HANDOK, a leading innovation-driven pharmaceutical/healthcare company in Korea, develops, manufactures and distributes healthcare solutions to improve health and quality of life for all. Handok has a core business focus in diabetes, cardiovascular, oncology, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, has grown as a joint venture with Hoechst/Aventis/Sanofi and has established strategic
collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit http://www.handok.co.kr.

Amaliya Ilyasova
OCT Clinical
+7 981 709 20 60
email us here


Source: EIN Presswire